“Real world” eligibility for aducanumab-Reference-Cited by-同舟云学术

“Real world” eligibility for aducanumab

Published:2021-07-31 Issue:10 Volume:69 Page:2995-2998
ISSN:0002-8614
Container-title:Journal of the American Geriatrics Society
language:en
Short-container-title:J Am Geriatr Soc

Author:

Canevelli Marco¹²^ORCID,Rossi Paolo Dionigi³,Astrone Paolo⁴,Consorti Ernesto⁵,Vanacore Nicola²,Cesari Matteo⁶⁷^ORCID

Affiliation:

1. Department of Human Neuroscience Sapienza University Rome Italy

2. National Center for Disease Prevention and Health Promotion National Institute of Health Rome Italy

3. Geriatric Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy

4. Subacute Care Unit Azienda Socio Sanitaria Territoriale (ASST) Lodi Lodi Italy

5. Fellowship in Geriatrics and Gerontology University of Milan Italy

6. Geriatric Unit IRCCS Istituti Clinici Scientifici Maugeri Milan Italy

7. Department of Clinical Sciences and Community Health University of Milan Milan Italy

Publisher

Wiley

Subject

Geriatrics and Gerontology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgs.17390

Reference14 articles.

1. FDA's Decision to Approve New Treatment for Alzheimer's Disease. FDA; 2021.https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease.

2. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

3. Evaluation of Aducanumab for Alzheimer Disease

4. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Profile of the Italian Centers for Cognitive Disorders and Dementia in the Context of New Drugs in Alzheimer’s Disease;Journal of Alzheimer's Disease;2024-09-10

2. A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer’s disease (AD);Bioorganic & Medicinal Chemistry;2024-09

3. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission;The Lancet;2024-08

4. Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general population;2024-02-29

5. Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort;Journal of Neurology;2024-02-21